Abstract
<div>Abstract<p><b>Purpose:</b> Aggressive cutaneous squamous cell carcinoma (cSCC) is often a disfiguring and lethal disease. Very little is currently known about the mutations that drive aggressive cSCC.</p><p><b>Experimental Design:</b> Whole-exome sequencing was performed on 39 cases of aggressive cSCC to identify driver genes and novel therapeutic targets. Significantly, mutated genes were identified with MutSig or complementary methods developed to specifically identify candidate tumor suppressors based upon their inactivating mutation bias.</p><p><b>Results:</b> Despite the very high-mutational background caused by UV exposure, 23 candidate drivers were identified, including the well-known cancer-associated genes <i>TP53</i>, <i>CDKN2A</i>, <i>NOTCH1</i>, <i>AJUBA</i>, <i>HRAS</i>, <i>CASP8</i>, <i>FAT1</i>, and <i>KMT2C</i> (<i>MLL3</i>). Three novel candidate tumor suppressors with putative links to cancer or differentiation, <i>NOTCH2</i>, <i>PARD3</i>, and <i>RASA1</i>, were also identified as possible drivers in cSCC. <i>KMT2C</i> mutations were associated with poor outcome and increased bone invasion.</p><p><b>Conclusions:</b> The mutational spectrum of cSCC is similar to that of head and neck squamous cell carcinoma and dominated by tumor-suppressor genes. These results improve the foundation for understanding this disease and should aid in identifying and treating aggressive cSCC. <i>Clin Cancer Res; 20(24); 6582–92. ©2014 AACR</i>.</p></div>
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
